{"id":"melphalan-prednisone-velcade","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Melphalan damages DNA in rapidly dividing myeloma cells. Prednisone provides immunosuppressive and anti-inflammatory effects. Bortezomib inhibits the 26S proteasome, preventing degradation of pro-apoptotic proteins and causing accumulation of misfolded proteins, leading to myeloma cell death. The three-drug combination targets multiple pathways to overcome drug resistance.","oneSentence":"This combination uses melphalan (alkylating agent) and prednisone (corticosteroid) as backbone therapy with bortezomib/Velcade (proteasome inhibitor) to kill multiple myeloma cells through DNA damage, immunosuppression, and disruption of protein degradation pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:38.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed, elderly or transplant-ineligible patients)"}]},"trialDetails":[{"nctId":"NCT01208766","phase":"PHASE3","title":"Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2011-01","conditions":"Multiple Myeloma","enrollment":1503},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT02195479","phase":"PHASE3","title":"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-09","conditions":"Multiple Myeloma","enrollment":706},{"nctId":"NCT03412565","phase":"PHASE2","title":"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-26","conditions":"Multiple Myeloma","enrollment":265},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT03217812","phase":"PHASE3","title":"A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-23","conditions":"Multiple Myeloma","enrollment":220},{"nctId":"NCT01190787","phase":"PHASE2","title":"Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone","status":"COMPLETED","sponsor":"European Myeloma Network B.V.","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":150},{"nctId":"NCT00734149","phase":"PHASE2","title":"Bortezomib With Melphalan and Prednisone for Multiple Myeloma","status":"COMPLETED","sponsor":"Duke University","startDate":"2004-07","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT01063179","phase":"PHASE3","title":"Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2006-05","conditions":"Multiple Myeloma","enrollment":511},{"nctId":"NCT04151615","phase":"","title":"VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2018-11-15","conditions":"Multiple Myeloma","enrollment":203},{"nctId":"NCT05218603","phase":"","title":"Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2021-11-30","conditions":"Multiple Myeloma, Non-eligible for Autologous Stem Cell Transplantation (ASCT)","enrollment":100},{"nctId":"NCT03742297","phase":"PHASE3","title":"Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2018-10-22","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":462},{"nctId":"NCT02112175","phase":"PHASE3","title":"Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-04-30","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT02773550","phase":"PHASE4","title":"Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma","status":"TERMINATED","sponsor":"Basque Health Service","startDate":"2014-01","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT01818752","phase":"PHASE3","title":"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-07-08","conditions":"Multiple Myeloma","enrollment":955},{"nctId":"NCT02145598","phase":"PHASE2, PHASE3","title":"Treatment Optimization in Patients With Untreated Multiple Myeloma","status":"TERMINATED","sponsor":"Dr. med. Lars-Olof Muegge","startDate":"2013-08","conditions":"Multiple Myeloma","enrollment":85},{"nctId":"NCT01237249","phase":"PHASE2","title":"Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2011-02","conditions":"Multiple Myeloma","enrollment":250},{"nctId":"NCT00799539","phase":"","title":"A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen-Ortho Inc., Canada","startDate":"","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02474563","phase":"","title":"Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2011-05","conditions":"Multiple Myeloma","enrollment":171},{"nctId":"NCT00911859","phase":"PHASE2","title":"A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-06","conditions":"Multiple Myeloma","enrollment":118},{"nctId":"NCT00691704","phase":"PHASE2","title":"Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy","status":"COMPLETED","sponsor":"Cristina Gasparetto","startDate":"2008-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT00507416","phase":"PHASE3","title":"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":502},{"nctId":"NCT00002905","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Centro di Riferimento Oncologico - Aviano","startDate":"1995-06","conditions":"Lymphoma","enrollment":20},{"nctId":"NCT00652041","phase":"PHASE4","title":"Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2007-01","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT00443235","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma More Than 65 Years Old","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2005-03","conditions":"Multiple Myeloma","enrollment":260},{"nctId":"NCT00388635","phase":"PHASE1, PHASE2","title":"Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2004-04","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT00461747","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma Under 65 Years","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":390},{"nctId":"NCT00111319","phase":"PHASE3","title":"VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2004-12","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT00320476","phase":"PHASE2","title":"VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates","status":"COMPLETED","sponsor":"Korean Multiple Myeloma Working Party","startDate":"2006-04","conditions":"Multiple Myeloma","enrollment":35},{"nctId":"NCT00358020","phase":"PHASE2","title":"Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2004-11","conditions":"Multiple Myeloma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Melphalan/Prednisone/Velcade","genericName":"Melphalan/Prednisone/Velcade","companyName":"PETHEMA Foundation","companyId":"pethema-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses melphalan (alkylating agent) and prednisone (corticosteroid) as backbone therapy with bortezomib/Velcade (proteasome inhibitor) to kill multiple myeloma cells through DNA damage, immunosuppression, and disruption of protein degradation pathways. Used for Multiple myeloma (newly diagnosed, elderly or transplant-ineligible patients).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}